This paper shows that the presence of conditional staging in R&D (Research & Development) has a critical impact on portfolio risk, and changes diversication arguments when a portfolio is constructed. When R&D projects exhibit optionlike characteristics, correlation between projects plays a more complicated role than traditional portfolio diversication would suggest. Real option theory argues that research projects with conditional phases have option-like risk and return properties, and are dierent from unconditional projects. We show that although the risk of a portfolio always depends on the correlation between projects, a portfolio of conditional R&D projects with real option characteristics has fundamentally dierent risk than a portfolio of unconditional projects. When conditional R&D projects are negatively correlated, portfolio risk is hardly reduced by diversication. When projects are positively correlated, however, diversication is more eective than these tools predict.
Introduction
If the outcomes of a rm's endeavors are unknown, a key strategy to deal with such risk is betting on more than one horse. Successful R&D policy therefore requires the selection and development of several concurrent alternatives, known as diversication. Additionally, in order to timely abandon unprotable projects, R&D management often involves breaking an individual R&D project into stages, so that certain requirements must be met before it can enter the next development phase. The sequential nature then brings conditionality to the project and causes R&D projects to exhibit option-like behavior, which complicates the diversication argument. This paper examines diversication when conditional staging is present in an R&D portfolio, and shows that reliance on traditional diversication arguments can be quite misleading. As compared to diversication of traditional (unconditional) projects, conditionally staged projects are less sensitive to changes in correlation and risk is therefore more dicult to diversify. Our results show that negative correlation amongst conditionally staged projects makes diversication a less eective instrument to eliminate risk than for unconditional projects. Positive correlation amongst conditionally staged projects, however, makes diversication more eective.
Real options analysis has become a well-established R&D project valuation technique for intertemporal risky investments in R&D. Rooted in nancial theory, Myers (1977) was the rst to describe real options as the opportunities to purchase real assets on possibly favorable terms . In their seminal paper, Black and Scholes (1973) consider equity of a real, levered rm as an option on its Email address: vanbekkum@few.eur.nl, pennings@few.eur.nl, jsmit@few.eur.nl (Sjoerd van Bekkum * , Enrico Pennings and Han Smit). entity value. In the strategy literature, Bowman and Hurry (1993) and Bettis and Hitt (1995) propose real options theory as an alternative lens for looking at technology investments that closely resemble the behavior and characteristics of real options. In the R&D literature, Thomke (1997) indeed shows empirically that exibility under uncertainty allows rms to continuously adapt to change and improve products. Hartmann and Hassan (2006) provide empirical evidence that real option analysis is used as an auxiliary valuation tool 1 in pharmaceutical project valuation. In this context, a basic implementation is provided by Kellogg and Charnes (2000) , and more sophisticated option valuation models for pharmaceutical research have been developed by Loch
and Bode-Greuel (2001) . Lee and Paxson (2001) view the R&D process and subsequent discoveries as sequential (compound) exchange options. Cassimon et al. (2004) provide an analytical model to value the phased development of a pharmaceutical R&D project. The empirical literature also conrms that R&D yields the positively skewed distribution of returns that is typical for options. For instance, Scherer & Harho (2000) show that the top 10% of the investigated inventions and innovations captured 48 to 93 percent of total sample returns. They refer to Nordhaus (1989) , who postulates that 99.99%
of the tens of thousands of invention patents issued each year are worthless, but that the remaining 0.01% have high values.
1 The fundamental dierence between real options and traditional Discounted Cash Flow (DCF) valuation lies in the exibility to adapt when circumstances change. Whereas DCF valuation xes an investment decision once and for all, an option is the right (not the obligation) to invest in R&D at some future date. If future circumstances are favorable, the option will be exercised; if not, the option will expire without any further cost. Such freedom of choice enables an investor to timely abandon the project so that further losses are avoided. Therefore, many unfavorable investments (with limited downside risk) can be nanced by a few highly protable investments (with unlimited upside potential). Protable investments will account for the majority of returns, so the return distribution becomes positively skewed. Although most real options studies have primarily examined projects in isolation, Engwall (2003) argues that every project takes o from, or is executed in, an organizational context. Real options should therefore also be considered as part of a portfolio. Brosch (2001) contemplates on the inuence of interacting real options within projects. These positive and negative interactions between options make a portfolio's value non-additive. Our focus, however, is on option interactions between projects, and we focus on the risk of the portfolio. Smith and Thompson (2003, 2005) postulate a project selection strategy in sequential petroleum exploration, where the outcome of the prior drillings can be observed before investing in the next drilling. We are also involved with real option selection, but focus on simultaneous (non-sequential) development. Multiple assets have been examined by Wörner et al. (2002 Wörner et al. ( , 2003 , who describe a rm that conducts several R&D projects as a`basket option', or an option on a set of stochastic variables. Yet, as they focus on the value of a single claim that pertains to many random variables, their analysis does not derive results for portfolio management (which inherently deals with the selection between multiple claims). In our argument below, we examine conditional projects (or rms) and how their individual risk-and return properties aect the overall risk of a portfolio.
When constructing an R&D portfolio, the selection of candidates comprises many important, non-monetary considerations: for example, Prencipe and Tell (2001) show that rms try to capture synergies that stem from learning processes. Several studies have therefore aimed to integrate risk diversication with expected costs and benets, inter-project synergies, externalities, R&D quality and overall t with the business strategy. In this tradition, Linton, Walsh, and Morabito (2002) developed a framework that combines both quantitative and qualitative measures to rank and select the projects in a portfolio.
Furthermore, Martino (1995) This paper is organized as follows: in Section 2, the theory behind a portfolio of real options is conveyed. In Section 3 we present the model and its results, and answer the question why pharmaceutical rms focus instead of diversify by using our model. In Section 4, we discuss managerial implications and conclude. In the Appendices A and C, a proof of our ndings is provided, as well as a means to extend our analysis to a more realistic setting.
Conceptual Framework
An opportunity to invest can turn out favorably or unfavorably. In the rst case the investor makes a prot, and otherwise he looses no more than the initial amount invested. Such limited liability causes the investor's payo structure to be non-linear, and further investment is conditional on a positive value development in the future. This is the key characteristic of a nancial option.
The familiar payo structure of both the investor and an individual European option at maturity is shown in Figure 1A : if the stock is valued at less than the investment (equal to $1) , the call is worthless. The exercise price is analogous to the present value of the investment that is made after the initial investment to acquire the option. If the stock price is larger than $1, its value rises one-to-one with increases in the stock price. The stock price is analogous Figure 1a shows the value of a single call option at expiration. Figure 1b shows the return distribution of a population of call option returns, where the shaded part is truncated.
to the present value of the project's cash ows 6 . So at expiration the project value can either be zero, or larger than zero. when the underlying stock is not worth the exercise price, the option will remain unexercised. Therefore, the shaded area of the distribution is nonexistent 6 The analogy holds also for the other variables that are needed to calculate the value of an option: the variance of stock is analogous to the project's cash ow volatility, and the time to maturity is analogous to the investor's time available to defer a next investment. The risk-free rate represents the time value of money in both the real and nancial setting.
and the distribution seizes to be symmetrical 7 .
If the projects are without conditional staging, the shaded area would exist, the distribution would be symmetrical and by a 'perfect hedge', a riskless portfolio can be created: when two equity shares are perfectly negatively correlated, one goes down by an equal amount if the other goes up and vice versa 8 , so that all deviation is oset. In line with Markowitz (1952), we call this hedging mechanism the diversication eect on the risk of a portfolio.
However, if the projects are conditionally staged, project values are optionlike distributed, above-average returns are no longer oset by below-average returns and Markowitz's (1952) diversication principle is no longer valid.
Because the payo from a call cannot fall below zero, the option already provides insurance against the negative payos by nullifying those payos that are lower than the exercise price. As a consequence, these would-be-negative payos are no longer available for diversication, and constructing a riskless portfolio is no longer possible. In a portfolio of options, paradoxically, the key characteristic of an option limits downside risk of the individual project, but complicates diversication and increases risk of the portfolio. In line with
Jensen's Inequality, we call this the`convexity eect', which may partly oset the diversication eect. In Appendix A, we derive this result as we examine the variance of a conditionally staged portfolio more explicitly.
7 Because the value of a project is a random variable and the option value on the project is a convex function of the project value, it is known that
where OV is the value of the option and x is the project value. In this particular case, this means that the expected value of the option on the project is larger than an option on the expected value of the project. This inequality is known as Jensen's Inequality, and is caused by the nonlinear transformation of an option value on some underlying asset. 8 That is, when uncertainty is constant and equal for both shares.
In the next section, we will develop a Monte Carlo simulation model to show the eect of risky projects on a portfolio of R&D projects. The procedure is straightforward and can easily be used in practice with other portfolio selection criteria. But before we proceed, a proper denition of the key concepts is appropriate. This paper is focused on the risk of a portfolio, and is therefore a supplement to other portfolio selection criteria we already mentioned. Their importance notwithstanding, for the sake of argument we group all these criteria under the name of non-diversication criteria . The uncertainty in our portfolio is completely determined by how the market value of projects develops: we conne our analysis to the relation between market values of projects, and assume the project costs to be independent and known. We prefer this setup because modelling more than one uncertainty would cause our results to become confounded. For more realistic settings, the procedure can be easily extended to accommodate two or more related stochastic processes such as uncertain costs and benets.
3 Methodology and Results
Simulation Model
To nd the volatility of an option portfolio, we need to estimate the volatility of payos for each option. The payos can be found by examining the lognormal value distribution of market prices for R&D projects, which are assumed to follow a geometric Brownian motion.
We start with two projects i {1, 2}. Unless we consider the special cases in Appendix A, it is not possible to determine the risk of an option portfolio ana-lytically because the joint distribution of options is not analytically tractable.
We therefore model the behavior of both end-of-R&D values projects V i by a simple normal distribution 9 , dened as follows:
where µ i is the project value, σ i is the standard deviation of project values and ε i is a random draw from a standard normal distribution. For each project i,
we calculate the option value OV i :
where X i is the investment, needed to start or acquire the project. To nd the volatility of an option, we repeat equations 1 and 2 R times and see how its values are distributed:
When both projects are technically related, samples need to be drawn from a bivariate standard normal distribution and the relatedness between market values is measured by means of a correlation coecient ρ 12 between ε 1 and ε 2 .
Hull (2006) describes how a bivariate standardized normal distribution can be constructed through Cholesky decomposition. For each simulation round, independent samples y 1 and y 2 are taken from a univariate standardized normal distribution and the correlated samples ε 1 and ε 2 are calculated as follows:
9 Our results also persist for other models of behavior.
From one set of independent samples y 1 and y 2 , we generate 21 pairs of correlated samples ε 1 and ε 2 (ranging from ρ 12 = −1.0 to ρ 12 = 1.0 with step size 0.10) by plugging in the independent sample values in equations 4 and 5 10 .
Because the value of a portfolio is simply the sum of the projects i,
the risk of the portfolio can be dened for each correlated sample ε 1 and ε 2 , similar to the variance of the option value. An estimate of this variance is based on a simulation of portfolios and averaging over R:
3.2
Simulation Results 10 Usually, a triangular matrix needs to be constructed that represents a consistent variance-covariance matrix (VCV). In the two-variable case, however, this is not necessary because any correlation structure between two variables is consistent as long as the correlation is between -1 and 1.
both separate and unrelated. In this situation, the projects are identical in value and in risk.
To illustrate the dierence between the actual portfolio risk and the calculated risk when using Markowitz, we have added a third, dashed lineσ 2 pf that shows the variance of the projects if we assume Markowitz diversication to be valid.
This would be appropriate if the separate projects would be unconditional and behave as equity shares. To construct the three lines, the following well-known formula to calculate portfolio variance is used:
The dierence lies in the interpretation of the correlation coecient ρ (the hor- The`convexity eect', however, limits the most severe value drops but leaves all positive development intact, so that project payos are non-linear and the value distribution becomes skewed. Figure 2 and Appendix A both show that when the value dynamics of individual projects can no longer be oset, naively applying Markowitz diversication may lead to signicant miscalculations of risk. This is caused by the interaction between diversication and convexity eects, which has both positive and negative consequences. When projects are positively correlated, the cushioning of convexity enhances diversication and overall risk becomes lower than under Markowitz. But when the projects are negatively correlated, the cushioning of convexity hampers the diversication eect, leading to a less eective hedge. As a consequence, options are more complex instruments for diversication than stock. In terms of the eect that correlation has on risk, the sensitivity of unconditional risk to changes in correlation is generally smaller than for unconditional risk, up to a correlation of about ρ = 0.70: especially for negatively correlated projects, diversication is hardly changing the portfolio's risk. Stated more precisely, the variance of a conditionally staged portfolio is compressed towards the cumulative variance for two independent options. The range of a conditionally staged portfolio is smaller than the range of an unconditional portfolio, but the minimum is higher than the unconditional portfolio's minimum. We can formulate the following hypotheses:
H1: Under positive correlation, conditionally staged projects diversify risk better than unconditional projects.
H2: Under negative correlation, unconditional projects diversify risk better than conditionally staged projects.
Robustness Analysis and General Applicability
The base case (Figure 2) shows what happens when two simple and identical options are out of the money: the investment hasn't been recovered yet. This setting is typical for many R&D projects. Figures 3a-d show results of simulated options that have a lower volatility (Figure 3a) , a dierent volatility (Figure 3b ), are at the money (Figure 3c ) or in the money (Figure 3d ). In all these situations, the convexity-eect persists. In Figure (a) , we halve the volatility so that the project is not in the money until the value equals µ + 2σ.
In R&D, this means that the project is not continued in about 97.5% of the cases and hardly any of these projects is available for risk diversication. As a consequence, the diversication eect is almost absent and all we see is the convexity eect: we might just as well not diversify at all. As a less extreme case, when volatilities dier, Figure (b) shows that portfolio risk is less sensitive to changes in correlation than in Figure 2 and diversication is still quite ineective. Please note the unit change on the y-axis, indicating that in this case, zero variance can not be achieved by naive calculation either. When the moneyness increases in Figure ( c) and (d), the curves move towards the straight line and our results become less distinct. This reects the familiar fact that options that are deeply in the money will behave similarly to the underlying stock. As a consequence, the convexity eect becomes less pronounced and the diversication eect starts to dominate. In R&D, this means that if the value of the project is much higher then its costs, conditional staging doesn't make a large dierence because the project will be exercised anyway.
A few general remarks are in order here. Many projects are funded by multiple nance or subsidy rounds and our simple calls represent the last phase. The pharmaceutical industry, for example, is typically characterized by six stages of development. This means that the condition of completing the sixth phase is conditional upon completion of the fth phase, which is conditional on the fourth phase, etcetera. These more realistic features can easily be modeled by using compound options in the simulation. In the compounded case, we are stacking`eect on eect'. This is not demonstrated here, because such simulation results are highly dependent on the success of entering the next 3.4
Implications
The implications of our results can be readily applied in any research policy that concerns simultaneous development. While various applications may illustrate the use of our ndings, we give an example that originates from the pharmaceutical industry. In this sector, many small rms succesfully focus on a few drugs, rather than become part of a portfolio of a large, diversied company. Why is risk diversication not necessary for small research ventures to be successful in such risky business? One argument would be that in the early stages of development, economies of scale (e.g. in marketing) are not feasible yet. Another would be that the R&D process is dierently organized for small ventures than for big companies. Our results give an additional argument for this behavior: a strong focus only marginally increases the risk of the portfolio while it may strongly contribute to non-diversication criteria (such as synergies and spillovers) and preserve the upward potential. We also provide an argument in favor of active portfolio management: as portfolios need restruc-12 At the same time, the number of possible correlations is smaller than 63. If, for instance, two projects c 1 and c 2 have a negative correlation of 0.99, the third cannot be highly correlated with both at the same time. In this three-variable case, the correlation between c 1 and c 2 and a third, single option can only be dened on the complete interval [-1, 1] when the correlation of the two projects c 1 and c 2 is held constant at ρ = 0.
turing when projects evolve and become less risky, the venture may be sold to a diversied company.
If conditionally staged projects are positively correlated, their combined value is less volatile than standard portfolio theory might suggest. Portfolio risk is likely to be overestimated because the diversication eect is cushioned by the convex nature of options. In terms of diversication, these projects are good candidates for portfolio selection. If, conversely, drug development projects are negatively correlated and the uncertainty is high enough to let progress be conditionally staged, then the cushioning of convexity causes diversication to be less eective than would be expected from Markowitz. As time progresses, the results of these R&D programs improve and become less uncertain, the cushioning disappears and the projects will behave more stock-like. In these later stages, diversication becomes more important in portfolio selection as the risk becomes more sensitive to changes in correlation.
It may be useful to provide examples of positively and negatively correlated risk as well. Positively correlated risk can partly be ascribed to nondiversiable market risk. Another part may be ascribed to the medical context, where positively correlated projects may represent two or more drug development programs projects that will lead to`complementary treatment' of illness: a rst example is the case for the treatment of HIV, where (due to mutations) any mono-therapy is not able to suppress an HIV-infection and a combination of three drugs is prescribed. When the side eects of one drug become less severe, or if the eectiveness of one drug improves, the value of the other two drugs will increase as well, because the quality of the treatment increases. As a second example, we can think of drugs that treat disorders that are strongly related such as lung cancer and cardiovascular diseases. Often, both are the result of a common cause such as an unhealthy lifestyle. When patients can be treated for one disease, the patient will live longer and the odds increase that he will suer from the second disease. Ironically, this is good news for investors as the market value of both drugs increases. An example of negatively correlated risk lies in two drug development programs that are substitutes:
if the value of one program goes up due to a major discovery, the value of the other project automatically goes down (for instance, when two development programs aim to cure similar diseases). The risk of negatively correlated projects is only marginally lower in a portfolio than for independent projects.
Therefore, although non-diversifcation arguments may provide good reason to combine these projects, risk reduction isn't one of them. Until the projects mature and risk has been diminished, negatively correlated risky projects are less attractive portfolio candidates for risk management.
We consider the pharmaceutical industry to be a well-chosen example for its active portfolio management also. It is evident that corporate risk diminishes as new ventures reach maturity. In Figure 1 , our framework indicates that ventures rst behave as the curvature, and later behave as the straight, dotted line.
The gentle slope of the curve shows that although the risk of positively correlated ventures is still higher than the risk of negatively correlated ventures, the dierence doesn't matter as much as standard portfolio theory predicts.
Therefore, structuring a portfolio to minimize variance is not as important in the early stages. When ventures mature, however, diversication becomes more important and the risk characteristics of positively and negatively correlated ventures become more pronounced. It may be wise to sell positively correlated ventures in this stage.
20
In this article we have shown that the presence of conditional staging in R&D invalidates diversication arguments when a portfolio is constructed. Under negative correlation, emphasis should be placed on other (non-diversication) arguments when constructing a portfolio whereas under positive correlation, the advantages of diversication are larger than one may expect from Markowitz diversication. We have also demonstrated that due to the convexity of highrisk projects, the sensitivity of portfolio risk to correlation is smaller for highrisk projects than for low-risk projects.
Implementation of our model is straightforward, and shows that the dierence in risk between high-risk and low-risk projects can be quite substantial: for two negatively correlated risky projects of about ρ = −0.5, the uncertainty is reduced by only 10%/50% = 20% as compared to low-risk uncertainty reduction. For ρ = +0.5, the uncertainty is increased by only 30%/50% = 60% as compared to low-risk uncertainty. These dierences can easily become more dramatic (in extreme cases, diversication becomes impossible), and our ndings are robust to changes in the parameter structure of the model. We have provided examples to show why this is important for the R&D portfolio of a drug developer.
Some extensions to the model can make it more suitable to analyze portfolio risk under more specic circumstances. One can easily construct a portfolio with projects that dier in volatility, time to maturity and moneyness. We have explained the possibility of compounding options when additional parameters (such as success probabilities) are known. Using a provided algorithm, it is easy to extend the analysis to a large portfolio, with each project having its own distinct features such as the required investment outlay, estimated date of completion and volatility of market value. The simulation procedure remains the same for several underlying stochastic processes and may include other case-specic peculiarities such as mean reversion, barriers or autocorrelation.
It is also possible to account for synergies on the cost side. Future research may hence yield similar results as ours, but from real-life data. For expositional purposes, however, all these extensions would unnecessarily complicate our
argument.
An important implication that follows from our work is that, when evaluating the risk of a portfolio of risky R&D opportunities, it is not sucient to merely examine the risk-return properties between projects: it is also important to determine the presence of staged conditionality before drawing conclusions on how appropriate a project is for reducing the risk of the portfolio. When additional information is available on project parameters to tailor the model to a specic problem, our framework could also be helpful in the formulation and assessment of research and development policy by public and private parties. 
where w 1 and w 2 are the appropriate weights. The key to an analytical derivation of the variances is recognizing the outcome possibilities that exist in each of the three correlation scenarios, and construct a single variance from there, using a variance decomposition formula that is dened as:
We will consider a portfolio of two simple investment opportunities (calls) that are exactly equal two each other. Both require an investment X that is, by assumption, equal to the expected value of the project (for ease of notation, we drop the subscript i that we introduced in Section 3.1):
As a consequence, for at the money options, each call will be distributed around E[V T ](again, we drop the subscript i):
Furthermore, since both calls are identical, we know that the probability of being in the money is equal for both calls i, j:
The cases of perfectly positive, negative or absent correlation dier only in the correlation that exist between two projects, and each will yield a dierent expression for the portfolio variance, as expressed in terms of the option components' variance in 9.
Perfectly positively correlated projects For ρ = 1, either both calls are in the money or both calls are out of the money. This means that the portfolio consists of two possible outcomes: V ar(pf |ρ = 1) = 4V ar(c
Perfectly independent projects
For ρ = 0, we know from equation 12 and equation 13that each option can be in the money or out of the money with equal probability. In this case, we can therefore distinguish 4 possible outcomes :
The variance of the rst two terms on the right hand side is equal to V ar(c + ), and the expected value for both is E[c + ]. Since the non-linear payo is accounted for in the last term, we can use Markowitz to nd the variance of the third term, which is simply the sum of the variances V ar(c 
This is exactly half of the variance found at ρ = +1, a nding that corresponds with the simulation results.
Perfectly negatively correlated projects
For ρ = −1 and at the money options, we know that either one call or the other is in the money. But because both projects can never jointly be in-or out of the money at ρ = −1, this simply means that the variance is equal to either the variance of one call, or that of the other. More precisely, we can state that:
We can write the last line because the calls are identical under the given conditions. It follows directly that we can write:
V ar(P f |ρ = −1) = V ar(c + )
This demonstrates why in our results, the variance of a perfectly negatively correlated portfolio doesn't go to 0% in the limit but is of a magnitude between zero and the variance at ρ = 0. Indeed, diversication under these circumstances does not permit risk to be diversied away.
Appendix B: How to Generate Random Samples from a Multivariate Normal Distribution
In case a third stock enters our model, a third sample is drawn; ρ 13 and ρ 23 need to be dened in such a manner that the variances and covariance are consistent, for instance, if asset 1 and asset 2 strongly move together as well as asset 1 and 3 (i.e., the correlations ρ 12 and ρ 13 are highly positive), then the dynamics of asset 2 and 3 need to be positively related to some extent (i.e., ρ 23 needs to have a high positive value) as well. If we require 3 correlated samples from normal distributions, the required samples are dened as follows:
ε 2 = α 21 x 1 + α 22 x 1 
For the third sample, α 31 is to be chosen such that α 31 α 11 = ρ 31 , yielding α 31 = ρ 31 . Then α 32 is to be chosen such that α 31 α 21 + α 32 α 22 = ρ 32 , 
We conclude by the requirement that 
We can simply generalize this case to n by expanding the Choleski matrix in equation 15, for example to ε 4 = α 41 x 1 + α 42 x 2 + α 43 x 3 + α 44 x 4
and repeat this procedure. But correlations need to be chosen with more and more care as the number of projects increases. In case of 2 projects, the restriction imposed by (B2) implies that ρ 12 must be smaller than 1. Although not very demanding in the two-variable case, the requirements above pose more restrictions on the correlated projects for every project that enters the simulation. We initially consider a single drug. If we want to simulate two additional projects that both are correlated to this drug ρ 12 = ρ 13 = −0.9, 
